These Analysts Boost Their Forecasts On Acadia Pharmaceuticals
1. ACAD secured a favorable court ruling for NUPLAZID's patent protection. 2. The ruling extends protection against generics until 2038. 3. ACAD shares rose by 26.5% following the announcement. 4. Analysts raised price targets for ACADIA after the ruling. 5. Needham and HC Wainwright maintain 'Buy' ratings on ACAD.